GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Avacta Group PLC (OTCPK:AVCTF) » Definitions » EV-to-FCF

Avacta Group (Avacta Group) EV-to-FCF

: -10.58 (As of Today)
View and export this data going back to 2015. Start your Free Trial

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Avacta Group's Enterprise Value is $205.01 Mil. Avacta Group's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2023 was $-19.38 Mil. Therefore, Avacta Group's EV-to-FCF for today is -10.58.

The historical rank and industry rank for Avacta Group's EV-to-FCF or its related term are showing as below:

AVCTF' s EV-to-FCF Range Over the Past 10 Years
Min: -46.31   Med: -7.61   Max: -0.66
Current: -11.39

During the past 13 years, the highest EV-to-FCF of Avacta Group was -0.66. The lowest was -46.31. And the median was -7.61.

AVCTF's EV-to-FCF is ranked worse than
100% of 384 companies
in the Biotechnology industry
Industry Median: 4.38 vs AVCTF: -11.39

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-19), Avacta Group's stock price is $0.5906. Avacta Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was $-0.202. Therefore, Avacta Group's PE Ratio for today is At Loss.


Avacta Group EV-to-FCF Historical Data

The historical data trend for Avacta Group's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avacta Group Annual Data
Trend Jul12 Jul13 Jul14 Jul15 Jul16 Jul17 Jul18 Dec20 Dec21 Dec22
EV-to-FCF
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.63 -1.48 -19.68 -13.59 -16.76

Avacta Group Semi-Annual Data
Jan13 Jul13 Jan14 Jul14 Jan15 Jul15 Jan16 Jul16 Jan17 Jul17 Jan18 Jul18 Jan19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
EV-to-FCF Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -13.59 - -16.76 -

Competitive Comparison

For the Biotechnology subindustry, Avacta Group's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Avacta Group EV-to-FCF Distribution

For the Biotechnology industry and Healthcare sector, Avacta Group's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Avacta Group's EV-to-FCF falls into.



Avacta Group EV-to-FCF Calculation

Avacta Group's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=205.012/-19.383
=-10.58

Avacta Group's current Enterprise Value is $205.01 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Avacta Group's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2023 was $-19.38 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Avacta Group  (OTCPK:AVCTF) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Avacta Group's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.5906/-0.202
=At Loss

Avacta Group's share price for today is $0.5906.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Avacta Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was $-0.202.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Avacta Group EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Avacta Group's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Avacta Group (Avacta Group) Business Description

Traded in Other Exchanges
Address
Unit 20, Ash Way, Thorp Arch Estate, West Yorkshire, Wetherby, GBR, LS23 7FA
Avacta Group PLC is a United Kingdom-based biotechnology company. The company offers its products through three segments that are Diagnostics, Therapeutics, and Animal Health. The company is developing novel cancer immunotherapies combining its two proprietary platforms Affimer biotherapeutics and precision tumor-targeted chemotherapy. The company operates in the United Kingdom, France, South Korea, Rest of Europe, Asia, and North America.

Avacta Group (Avacta Group) Headlines

From GuruFocus

Avacta announces AffyXell $7.3 Million Series A Financing

By Business Wire Business Wire 02-01-2021

Avacta Announces License Agreement With POINT Biopharma Inc.

By Business Wire Business Wire 01-07-2021

Avacta Appoints Dr Christina Coughlin as Non-Executive Director

By Business Wire Business Wire 03-21-2022

Avacta's Diagnostic Division Achieves ISO 13485 Certification

By Business Wire Business Wire 07-14-2021

Avacta Group plc Signs License Agreement With Astrea Bioseparations

By Business Wire Business Wire 12-21-2020

First Patient Dosed in the US in Avacta's AVA6000 Phase 1 Clinical Study

By Business Wire Business Wire 04-27-2023

LG Chem Renews License Triggering Payment to Avacta

By Business Wire Business Wire 06-30-2022

Avacta Announces SARS-CoV-2 Rapid Antigen Test Clinical Collaboration

By Business Wire Business Wire 08-07-2020